Scholarlink

<p>Metabolic Dysfunction-Associated Steatohepatitis (MASH), the advanced stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a leading cause of chronic liver disease, driving cirrhosis, liver cancer, and mortality. With metabolic, genetic, and environmental factors at play, early detection and treatment are critical. This review highlights the latest breakthroughs in MASH pathophysiology, cost-effective noninvasive diagnostics, and emerging therapies, emphasizing the urgency of accessible solutions to combat this growing global health crisis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月5日

查看全文
  • Milkiyas T. Tantu,
  • Fatema Z. Farhana,
  • Farjana Haque,
  • Kevin M. Koo,
  • Liang Qiao,
  • Allen G. Ross,
  • Muhammad J. A. Shiddiky

摘要

Metabolic Dysfunction-Associated Steatohepatitis (MASH), the advanced stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a leading cause of chronic liver disease, driving cirrhosis, liver cancer, and mortality. With metabolic, genetic, and environmental factors at play, early detection and treatment are critical. This review highlights the latest breakthroughs in MASH pathophysiology, cost-effective noninvasive diagnostics, and emerging therapies, emphasizing the urgency of accessible solutions to combat this growing global health crisis.